Opinion|Videos|December 15, 2023
Evaluating the L-MIND and RE-MIND2 Trials in the Real-World Setting
Author(s)Matthew A. Lunning, DO, FACP
Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP
3
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
4
Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma
5